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Background
Recent studies suggest increased admission rates for
food-related anaphylaxis. T h eo n l ye f f e c t i v et r e a t m e n t
for anaphylaxis is prompt administration of
epinephrine.
Objectives
To characterize treatment practices of initial allergic
reactions inside and outside health care facilities (HCF).
Methods
Individuals with an allergist-confirmed peanut allergy
were recruited from the Montreal’s Children Hospital
and Canadian food allergy advocacy organizations. Data
were collected on initial allergic reactions to peanut and
treatment inside and outside HCFs.
Results
Of 751 individuals who had an allergic reaction to pea-
nut, 613 responded (81.6%). Initial reactions were mild in
28.4% (95% CI, 25.0-32.1%), moderate in 50.6% (46.6-
54.6%), and severe in 20.9% (17.8-24.3%). Average age of
initial reaction was 2.1 years (2.0-2.3). Among partici-
pants, 11.6% (9.1-14.7%) were diagnosed with peanut
allergy (based on skin and IgE testing) prior to the initial
reaction. Of the 613 participants, 32.1% (28.5-36.0%)
were treated in HCFs only, 51.7% (47.7-55.7) outside
HCFs only, and 16.2% (13.4-19.3%) in both. 21.3% (17.0-
26.3%) of all reactions treated in HCFs received epi-
nephrine (table) versus only 3% (1.8-5.1%) treated out-
side. Of those with moderate or severe initial reactions,
58.2% (53.5-62.8%) were treated in HCFs, and 23.9%
(19.1-29.6%) of these received epinephrine. See table 1.
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Table 1
% of Respondents Receiving each Treatment in HCF % of Respondents Receiving each Treatment outside
HCF
Epinephrine +/-
other medications%
(95% CI)
Other medications
(excluding
epinephrine)
None Epinephrine +/-
other
medications
Other medications
(excluding
epinephrine)
None
All reactions 21.3 (17.0-26.3) 50.7 (45.0-56.4) 28.0 (23.2-33.5) 3.0 (1.8-5.1) 47.2 (42.6-51.8) 49.8 (45.2-54.4)
Severity
Mild 4.9 (1.5-16.2) 39.0 (25.6-54.4) 56.1 (40.1-70.2) 0.0 (0.0-2.6) 50.4 (41.1-58.5) 49.6 (41.5-57.8)
Moderate 15.1 (10.4-21.5) 54.1 (46.3-61.7) 30.8 (24.1-38-4) 4.3 (2.3-7.8) 46.8 (40.4-53.2) 48.9 (42.5-55.4)
Severe 38.5 (29.4-48.6) 50.0 (40.1-59.9) 11.5 (6.5-19.4) 4.5 (1.8-11.2) 43.2 (33.3-53.7) 52.3 (41.9-62.5)
Peanut allergy
diagnosed prior to
reaction
Yes 17.2 (7.7-34.8) 48.3 (31.3-65.7) 34.5 (20.0-52.9) 6.5 (2.3-17.6) 67.4 (52.8-79.2) 26.1 (15.6-40.4)
No 20.9 (16.0-26.8) 53.6 (47.0-60.2) 25.5 (20.1-31.6) 2.7 (1.4-5.0) 44.7 (39.4-50.0) 52.6 (47.3-58.0)
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Almost 50% of individuals with potentially life-threaten-
ing initial reactions are not treated in HCFs. Further, for
those with moderate and severe reactions treated in
HCFs, there is substantial underuse of epinephrine.
Thus, it is crucial to establish, distribute, and monitor
treatment guidelines that would improve treatment
practices of food-related allergic reactions.
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